Citicoline in Acute Ischemic Stroke: Case Report
DOI:
https://doi.org/10.26911/theijmed.2024.09.03.03Abstract
Background: Stroke is the third most common disease after heart disease and cancer and a leading cause of disability worldwide. The most common type of stroke is non-hemorrhagic stroke (SNH) or Acute Ischemic Stroke, which accounts for about 85-87% of all cases. The purpose of this case report is to examine the benefits of citicoline in a patient with SNH.
Case Presentation: In this case, a 63-year-old man was admitted to the Emergency Room of the Agung Mulia Inpatient Clinic on February 25, 2023 with complaints of inability to move his right arm and leg since 5 days before entering the clinic. The complaint was felt suddenly when the patient woke up in the morning. The patient also complained of weakness and difficulty speaking and slurred speech accompanied by difficulty swallowing. The voice could still speak but was unclear but the patient understood what was being said to him. Other complaints such as headaches, nausea, vomiting, bowel and urination disorders, and fainting were denied by the patient. The patient was treated at a hospital near his house on February 21, 2023 and underwent a CT scan of the head and was treated as an outpatient. The results of the CT scan on February 21, 2023, axial section of the head without intravenous contrast, obtained the following results: Infraterritorial cerebellum and 4th ventricle appear normal, Supreterritorial hypodense lesions appear on the left lateral periventricular and in the left parietal, No midline shift, Cortical sulci and prominent ventricular system. It was concluded that the left lateral periventricular and left parietal cerebral infarction were in accordance with Non-Hemorrhagic Stroke (SNH). Senile cerebral atrophy. Based on anamnesis, physical examination, and supporting examinations. The clinical diagnosis in this case was right hemiparesis and paresis of nerves VII, IX, and X, et causa non-hemorrhagic stroke (SNH) with electrolyte disorders (Electrolyte Imbalance), given general and specific management.
Results: For general management that can be given is semi-fowler position, oxygen administration, administration of antihypertensive drugs and maintaining fluid and nutritional intake. While specific management with pharmacology by administering citicoline and clopidogrel is given to this patient.
Conclusion: Citicoline works to prevent brain damage (neuroprotection) and helps the formation of cell membranes in the brain (neurorepair). The benefits of citicoline in this patient are seen in motor and neurological improvements based on NIHSS assessments.
Keywords:
Citicolin, stoke, non-hemorrhagic strokeReferences
Mukherjee D, Patil CG. Epidemiology and the global burden of stroke (2011). World Neurosurg. 76: S85–90. DOI: 10.1016/j.wneu.2011.07.023
Feigin VL, Lawes CM, Bennett DA, Anderson CS (2003). Stroke epide-miology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2: 43–53. DOI: 10.1016/s1474-4422(03)00266-7.
Davalos A, Alvarez-Sabin J, Castillo J, et al (2012). for the International Citicoline Trial on Acute Stroke (ICTUS) Trial Investigators. Citicoline in the treatment of acute ischaemic stroke: an international, randomized, multicentre, placebo-controlled study (ICTUS trial). Lancet. 380: 349–357. DOI: 10.10-16/S0140-6736(12)60813-7 .
Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, et all, (2010). Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 15;375(9727): 1695-703. DOI: 10.10-16/S0140-6736(10)60491-6.
Agarwal A, Vishnu VY, Sharma J, Bhatia R, Garg A, Dwivedi S (2022). Citicoline in acute ischemic stroke: A rando-mized controlled trial. PLoS ONE. 17(5): e0269224. DOI: 10.1371/jour-nal.pone.0269224.
Secades JJ, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Martínez-Vila E, Ríos J, Oudovenko N (2016). Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. J Stroke Cerebrovasc Dis. 25(8):1984-96. DOI: 10.1016/j.jstrokecerebro-vasdis.2016.04.010.
Sahota P, Savitz SI (2011). Investigational therapies for ischemic stroke: neuro-protection and neurorecovery. Neurotherapeutics. 8: 434–51. DOI: 10.1007/s13311-011-0040-6
Saver JL (2010). Target brain: neuropro-tection and neurorestoration in ischemic stroke. Rev Neurol Dis. 7 (1): S14–21. https://pubmed.ncbi.-nlm.nih.gov/20410866/
Da´valos A, Castillo J, Alvarez-Sabı´n J, et al (2002). Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke. 33:2850–2857. DOI: 10.1161-/01.str.000038691.03334.71
Gutie´rrez-Ferna´ndez M, Rodrı´guez-Frutos B, Fuentes B, et al (2012). CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke. Neurochem Int. 60:310–317. DOI: 10.1016/j.neuint.2011.12.015
Clark WM, Warach SJ, Pettigrew LC, Gammans RE, Sabounjian LA, and the Citicoline Stroke Study Group (1997). A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology. 49: 671–78. DOI: 10.12]]]]]]]]12/wnl.49.3.671
Clark WM, Williams BJ, Selzer KA, Zweifler RM, Sabounjian LA, Gammans RE (1999). A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke. 30: 2592–97. DOI: 10. 1161/01.str.30.12.2592
Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE, and the Citicoline Stroke Study Group (2001). A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology. 57: 1595–602. DOI: 10.1212/wnl.57.9.1595
Jasielski P, Piędel F, Piwek M, Rocka A, Petit V, Rejdak K (2020). Application of Citicoline in Neurological Dis-orders: A Systematic Review. Nutri-ents. 12(10):3113. DOI:: 10.3390/-nu12103113.
Kuriakose D, Xiao Z (2020). Pathophysio-logy and treatment of stroke: Present status and future perspectives. Int J Mol Sci. 21(20): 1–24. DOI: 10.3390/ijms21207609
Mutiarasari D (2019). Ischemic Stroke: Symptoms, Risk Factors, and Preven-tion. Jurnal Ilmiah Kedokteran Medika Tandulako, 1(1): 60–73. https://scholar.google.co.id/citations?view_op=view_citation&hl=en&user=vLniVygAAAAJ&citation_for_view=vLniVygAAAAJ:MXK_kJrjxJIC
Doijad RC, Pathan AB, Pawar NB, Baraskar SS, Maske VD, Gaikwad SL (2012). Therapeutic Applications of Citicoline and Piracetam as Fixed Dose Combination. Asian J Biomedical and Pharm Sci. 2(12): 15-20. https://ww-w.alliedacademies.org/articles/therapeutic-applications-of-citicoline-and-piracetam-as-fixed-dose-combination
Qureshi I, Endres JR (2010). Citicoline: a novel therapeutic agent with neuro-protective, neuromodulatory, and neuroregenerative properties. Nat Med J. https://api.semanticscholar.-org/CorpusID:16494787
Alvarez-Sabín J, Román GC (2013). The role of citicoline in neuroprotection and neurorepair in ischemic stroke. Brain Sci. 3(3):1395-414. DOI: 10.33-90/brainsci3031395.
Secades JJ, Gareri P (2022). Citicoline: pharmacological and clinical review, 2022 update. Rev Neurol. 75 (5): S0-S89. DOI: 10.33588/rn.75S05.202-2311
Kanyal N (2015). The science of ischemic stroke: pathophysiology & pharmacological treatment. Int J Pharm Res Rev. 4(10):65-84. https://www.rroij.com/open-access/the-science-of-ischemic-stroke-pathophysiology-pharmaco-logical-treatment-.pdf
Overgaard K (2014). The effects of citicoline on acute ischemic stroke: a review. J Stroke Cerebrovasc Disease. 23(7): 1764-69. DOI: 10.1016/-j.jstrokecerebrovasdis.2014.01.020
Premi E, Cantoni V, Benussi A, Gilberti N, Vergani V, Delrio I, Gamba M, et al, (2022). Citicoline Treatment in Acute Ischemic Stroke: A Randomized, Single-Blind TMS Study. Front. Neurol. 13:915362. DOI: 10.3389/-fneur.2022.915362.
Agarwal A, Vishnu VY, Sharma J, Bhatia R, Garg A, Dwivedi S (2022). Citicoline in acute ischemic stroke: A rando-mized controlled trial. PLoS ONE 17(5): e0269224. DOI: 10.1371/jour-nal.pone.0269224.
